Want to see AU:AN1 full AI Analyst Report?
Anagenics (AN1) AI Stock Analysis
Anagenics
(ASX:AN1)
Financial recovery with positive earnings and low debt is the main positive, tempered by cash flow issues; valuation at P/E of 30 offers moderate support.
Anagenics Business Overview & Revenue Model
Company Description
Anagenics Limited engages in the health wellness and beauty business. The company develops, manufactures, and markets anti-ageing hair care products under the évolis brand name; and skin, hair, and body care products under the Uspa brand name. It als...
How the Company Makes Money
null
Anagenics Financial Statement Overview
Summary
Profitability turnaround with positive net income and improved gross margins, supported by a clean balance sheet with very low debt. However, negative operating cash flow remains a significant concern.
Income Statement
68PositiveBalance Sheet
78PositiveCash Flow
22Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.16M | 5.16M | 4.75M | 10.80M | 9.11M | 6.95M |
| Gross Profit | 2.81M | 2.81M | 2.04M | 4.36M | 4.05M | 3.80M |
| EBITDA | 816.06K | 816.06K | -994.77K | -6.60M | -1.80M | -2.22M |
| Net Income | 308.47K | 308.47K | -1.24M | -7.49M | -2.67M | -3.65M |
Balance Sheet | ||||||
| Total Assets | 4.75M | 4.75M | 4.10M | 6.19M | 11.11M | 12.92M |
| Cash, Cash Equivalents and Short-Term Investments | 577.43K | 577.43K | 395.52K | 1.62M | 2.57M | 3.28M |
| Total Debt | 33.19K | 33.19K | 848.05K | 772.64K | 654.33K | 1.76M |
| Total Liabilities | 520.80K | 520.80K | 2.28M | 3.48M | 2.22M | 4.64M |
| Stockholders Equity | 4.23M | 4.23M | 1.83M | 2.71M | 8.90M | 8.29M |
Cash Flow | ||||||
| Free Cash Flow | -1.09M | -1.09M | -1.58M | -1.84M | -1.83M | -2.59M |
| Operating Cash Flow | -1.07M | -1.07M | -1.58M | -1.74M | -1.78M | -2.55M |
| Investing Cash Flow | -24.95K | -24.95K | 0 | -197.90K | -1.51M | -968.20K |
| Financing Cash Flow | 1.28M | 1.28M | 345.41K | 993.72K | 2.56M | 73.31K |
Anagenics Peers Comparison
Overall Rating
- AU:AN157Neutral
AU:HPC41Neutral
AU:EVE38Underperform
AU:SKN37Underperform
AU:HCT29Underperform
AU:NGS26Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 62Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% |
| AU:AN1 | 57Neutral | AUD 4.93M | 12.50 | 9.49% | ― | 5.83% | ― |
| AU:HPC | 41Neutral | AUD 1.61M | -0.37 | -239.37% | ― | ― | ― |
| AU:EVE | 38Underperform | AUD 4.76M | -2.11 | -49.07% | ― | -33.53% | 42.98% |
| AU:SKN | 37Underperform | AUD 6.97M | -0.44 | -430.23% | ― | -50.64% | -72.00% |
| AU:HCT | 29Underperform | AUD 12.14M | -3.79 | 1795.70% | ― | 0.72% | -486.96% |
| AU:NGS | 26Underperform | AUD 18.32M | -0.01 | -130.72% | ― | -33.05% | 94.22% |
* Consumer Defensive Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:EVE | EVE Health Group Limited | 0.01 | -0.02 | -56.67% | |
| AU:SKN | Skin Elements Limited | ― | ― | ― | |
| AU:HCT | Holista Colltech Limited | 0.03 | -0.04 | -57.69% | |
| AU:NGS | Nutritional Growth Solutions Ltd. | 0.02 | -0.00 | -9.52% | |
| AU:HPC | Hydration Pharmaceuticals Co. Ltd. | ― | ― | ― |
Anagenics Corporate Events
Anagenics Files Updated Corporate Governance Statement and Appendix 4G
Anagenics Limited has lodged its updated corporate governance statement for the year ended 30 June 2026, confirming that the document is available on its website and has been approved by the board as at 27 August 2026. The filing, made together with...
Anagenics Returns to Profit as Asset Backing Improves in FY26
Anagenics reported a modest 0.8% rise in revenue from ordinary activities to $5.16 million for the year ended 30 June 2026, while swinging to a net profit attributable to shareholders of $308,472 from a prior loss, reflecting a notable improvement in...
Anagenics Nears Maiden Profit as Cash Flow and Royalty Revenue Improve
Anagenics reported continued improvement in operational performance for the June quarter, with operating cash outflows of $0.08 million and positive trading, and it expects to deliver a maiden full-year profit for FY26 subject to audit. Operating cas...
Anagenics Appoints New Auditor Following ASIC-Approved Resignation
Anagenics Limited has announced a change of auditor, with the Australian Securities and Investments Commission consenting to the resignation of Connect National Audit Pty Ltd effective 24 July 2026. The company has appointed Stannards Audit Pty Ltd a...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 06, 2026